Journal of Frontiers in Multidisciplinary Research

Sustainable Management of Post-Consumer Pharmaceutical Waste: Assessing International Take-Back Programs and Advanced Disposal Technologies for Environmental Protection

Faith Osaretin Osabuohien
University of New Haven, Department of Chemistry, USA

* Corresponding Author: **Faith Osaretin Osabuohien**

Article Info

E-ISSN: 3050-9726
P-ISSN: 3050-9718
Volume: 03
Issue: 01
January-June 2022
Received: 19-03-2022
Accepted: 22-04-2022
Published: 21-05-2022
Page No: 483-499

Abstract
The improper disposal of post-consumer pharmaceutical waste poses significant threats to environmental and public health, as trace pharmaceuticals increasingly contaminate water bodies, soil, and food chains. This paper explores sustainable management practices for post-consumer pharmaceutical waste by critically assessing international drug take-back programs and evaluating advanced disposal technologies aimed at mitigating environmental hazards. Drawing on case studies from countries such as Sweden, Canada, the United States, and Japan, the study analyzes the effectiveness, scalability, and public engagement strategies of diverse pharmaceutical return schemes. These programs, often operated through pharmacies and municipal waste systems, demonstrate varying degrees of success influenced by regulatory frameworks, public awareness, and stakeholder collaboration. In addition to programmatic evaluation, this study examines advanced disposal technologies such as high-temperature incineration, plasma gasification, and emerging chemical neutralization processes. Each method is evaluated in terms of environmental impact, energy efficiency, cost-effectiveness, and feasibility for widespread adoption. Particular attention is given to challenges faced by low- and middle-income countries, including infrastructure deficits and regulatory inconsistencies, which hinder effective implementation of sustainable waste management practices. The findings suggest that while take-back programs are essential for public participation and upstream waste control, their success depends on strong policy mandates, continuous education, and incentives for proper disposal. Moreover, integrating green chemistry principles and decentralized treatment models can further enhance sustainability in pharmaceutical waste management. The paper concludes by proposing a comprehensive framework that combines community-based collection initiatives, robust regulatory oversight, and the deployment of advanced disposal technologies tailored to regional contexts. This integrated approach is vital for minimizing pharmaceutical pollution and ensuring long-term environmental protection.

DOI: https://doi.org/10.54660/.JFMR.2022.3.1.483-499

Keywords: Pharmaceutical Waste, Take-Back Programs, Advanced Disposal Technologies, Environmental Protection, Waste Management, Green Chemistry, Incineration, Plasma Gasification, Public Health, Sustainability

1. Introduction

Post-consumer pharmaceutical waste refers to expired, unused, or leftover medications discarded by consumers, often through household trash, sinks, or toilets. While typically overlooked in mainstream waste management discourse, this category of waste poses growing environmental and public health concerns. Pharmaceuticals such as antibiotics, analgesics, hormones, and psychiatric drugs, once released into the environment, can persist in water systems and soil, altering microbial activity, promoting antimicrobial resistance, and harming aquatic ecosystems. Inadequate disposal methods—especially in households without access to dedicated collection systems—have led to the detection of pharmaceutical residues in surface and groundwater globally. This contamination raises alarm about the long-term ecological impact and potential human exposure through drinking water and the food chain (Ariffin & Zakili, 2019; Sahota & Sharma, 2021).

Beyond environmental degradation, improper pharmaceutical disposal increases the risk of accidental poisoning, substance abuse, and the misuse of prescription drugs within communities. Vulnerable populations such as children and the elderly are particularly at risk, and the proliferation of unused medications contributes to the global opioid crisis and other medication-related public health challenges. The need for effective post-consumer pharmaceutical waste management has therefore become a global imperative, recognized by both health and environmental agencies (Banjoko, 2014; Santos, *et al*., 2013).

This paper aims to explore the sustainable management of post-consumer pharmaceutical waste by assessing the structure, effectiveness, and limitations of international drug take-back programs, as well as the environmental and operational viability of advanced disposal technologies. The scope includes comparative analyses of systems implemented in high-income and middle-income countries, highlighting lessons learned, best practices, and policy innovations (Bashaar, *et al*., 2017; Sartelli, *et al*., 2020). Furthermore, the paper evaluates the role of technological interventions such as high-temperature incineration, plasma gasification, and chemical neutralization in mitigating pharmaceutical pollution (Begum, *et al*., 2021; Hu, Logue & Robinson, 2020). By integrating insights from regulatory, technological, and community-based perspectives, the paper seeks to propose a holistic framework that supports environmental protection and public health through safe and sustainable disposal of pharmaceutical waste.

2. Methodology

This study adopted a qualitative systematic review methodology to explore sustainable management strategies for post-consumer pharmaceutical waste (PCPW), with a focus on global take-back programs and advanced disposal technologies. The selection of this method is based on its robustness in synthesizing cross-disciplinary knowledge, policy evaluation, and environmental systems thinking. A comprehensive literature search was conducted across peer-reviewed journals, doctoral dissertations, environmental and public health reports, and institutional publications spanning 2009 to 2022. Databases consulted include PubMed, Scopus, Google Scholar, and Web of Science. Search terms incorporated combinations of keywords such as "pharmaceutical take-back programs," "drug disposal," "post-consumer pharmaceutical waste," "reverse logistics," "pharmaceutical pollution," "environmental impact," "advanced oxidation," "green pharmacy," "household pharmaceutical waste," and "wastewater pharmaceutical residues."

Inclusion criteria required that selected documents explicitly discussed pharmaceutical waste management within the household or community context, provided insights into policy frameworks or technological interventions, and addressed environmental or health implications. Publications were excluded if they solely focused on hospital waste, veterinary medicines, or lacked environmental relevance. A total of 109 articles were retained after screening for relevance, thematic richness, and geographic diversity—encompassing case studies from the United States, Malaysia, Brazil, Ethiopia, Australia, and the European Union, among others.

To ensure analytical rigor, a thematic coding approach was used to extract key categories such as regulatory structures, technological innovations, public behavior and perception, circular economy models, and sustainability indicators. Insights from environmental pharmacology (Banjoko, 2014), pharmEcovigilance (Daughton & Ruhoy, 2011), and take-back logistics (Xie & Breen, 2014; Mahmood, 2010) were triangulated with real-world applications reported in Bangladesh (Begum *et al*., 2021), Afghanistan (Bashaar *et al*., 2017), and Malaysia (Ariffin & Zakili, 2019).

Case studies like the British Columbia Medications Return Program, the U.S. DEA National Take-Back Initiative, and EU's harmonization directives provided comparative policy frameworks. Advanced disposal technologies—such as advanced oxidation processes (Mazivila *et al*., 2019; Wang & Zhuan, 2020), ultrasound degradation (Costa *et al*., 2021), and photocatalysis (Oluwole *et al*., 2020)—were evaluated for efficacy, feasibility, and scalability using an environmental chemistry lens (Jjemba, 2018; Postigo & Richardson, 2014). Additionally, community engagement data were analyzed from behavioral surveys and public awareness studies (Vatovec *et al*., 2021; Lago *et al*., 2022; Ehrhart *et al*., 2020) to understand participation drivers and systemic barriers.

Findings were synthesized into a conceptual framework linking behavior, infrastructure, policy, and technology with environmental sustainability outcomes. The PRISMA flow diagram was adapted to trace document selection, while a systems-based flowchart was developed to illustrate the interdependent components of sustainable PCPW management. Data saturation and theoretical generalization were achieved through multi-case triangulation and inductive reasoning, strengthening the interpretive validity of recommendations made for scalable, equitable, and environmentally sound pharmaceutical waste solutions.



Fig 1: Flowchart of the study methodology

2.1 Sources and Types of Post-Consumer Pharmaceutical Waste

Post-consumer pharmaceutical waste originates primarily from households, encompassing a wide variety of products such as expired, unused, and leftover medications. These pharmaceuticals include both prescription medications and over-the-counter (OTC) drugs that are discarded for various reasons—ranging from changes in treatment regimens to non-completion of prescribed courses or the natural expiry of medicines over time (Benyam, 2019; Serwecińska, 2020). As populations grow and access to healthcare improves globally, the quantity of such waste has surged, contributing significantly to environmental and public health concerns. Understanding the sources and types of this waste is crucial for designing effective and sustainable waste management interventions.

One major source of pharmaceutical waste is expired medications stored in household medicine cabinets. Many individuals stockpile drugs in anticipation of future ailments or emergencies, leading to accumulation and eventual expiration. Medications that have passed their expiration dates are typically viewed as ineffective or unsafe for use and are discarded (Bucknall, 2020; Jasovský, *et al*., 2016). In the absence of structured disposal options, these expired drugs often end up in general waste bins, sinks, or toilets. Similarly, leftover medications from partially completed prescriptions constitute another major waste stream. Patients may discontinue use after symptom relief, experience side effects, or change medications based on medical advice, leaving substantial quantities unused (Šimatović & Udiković-Kolić, 2019). Figure 2 shows Sustainable COVID-19 plastic waste management practices in waste management during the COVID-19 pandemic presented by Das, *et al*., 2021.



Fig 2: Sustainable COVID-19 plastic waste management practices in waste management during the COVID-19 pandemic (Das, *et al*., 2021).

Unused medications can also result from over-prescription or the practice of prescribing large quantities of medication in a single fill to reduce pharmacy visits, especially in regions with limited access to healthcare facilities. This is particularly common for chronic disease treatments such as diabetes, hypertension, and asthma. When treatment regimens change or patients fail to adhere to prescribed dosages, large volumes of these drugs are discarded without proper management. Furthermore, antibiotics are frequently disposed of before completing the full course, exacerbating the problem of antimicrobial resistance by allowing sub-lethal concentrations to enter the environment (Carson, 2018; Jassim & Limoges, 2014).

The waste stream also includes a wide range of over-the-counter (OTC) medications, which are easily accessible without prescriptions and often used to treat minor ailments like headaches, colds, and digestive issues. Consumers frequently purchase these drugs in bulk or as part of promotional packages, many of which go unused or are used improperly. OTC drugs are commonly perceived as low-risk, which can lead to more careless handling and disposal practices. Despite their non-prescription status, these medications contain active pharmaceutical ingredients (APIs) that are equally capable of polluting water systems and affecting ecosystems (Chen, *et al*., 2021; Singer, *et al*., 2016).

In comparison, prescription medications are generally subject to stricter regulatory control in terms of distribution and usage, but they pose a greater risk when improperly discarded due to their potency and potential for misuse. Medications such as opioids, antidepressants, and antipsychotics fall into this category and are increasingly found in household waste streams. Their presence in the environment raises significant red flags, particularly regarding behavioral and developmental impacts on wildlife and potential drug resistance (Chung & Brooks, 2019; Jjemba, 2018). Process flow diagram of the newly proposed disposal method presented by Gill, *et al*., 2021 is shown in figure 3.



Fig 3: Process flow diagram of the newly proposed disposal method (Gill, *et al*., 2021).

A concerning aspect of post-consumer pharmaceutical waste lies in the lack of awareness and non-regulated disposal practices that prevail across many regions. In most households, expired or unused medications are casually thrown into the trash, flushed down toilets, or poured down sinks. These practices stem from a combination of limited public knowledge, absence of convenient return systems, and inadequate regulatory oversight. Wastewater treatment plants are not designed to effectively remove all pharmaceutical compounds, allowing significant quantities to enter rivers, lakes, and oceans. Even in countries with well-established environmental protection policies, household-level pharmaceutical disposal remains underregulated and often excluded from standard hazardous waste management frameworks (Corcoran, 2010; Singh, *et al*., 2016).

Moreover, cultural behaviors and socioeconomic factors influence how pharmaceutical waste is handled. In some settings, sharing unused medications with friends or family members is considered a form of help rather than a risky practice. In other cases, individuals hold on to expired or unused drugs in the hope that they may be useful again, rather than discarding them responsibly. The absence of a standardized and accessible pharmaceutical take-back program further compounds the problem. Even where programs exist, their effectiveness is hindered by low public participation due to inconvenience, lack of awareness, or distrust in waste management systems (Daughton, 2010).

In many developing countries, the situation is further complicated by poorly enforced pharmaceutical regulations and limited infrastructure for proper disposal. Open dumping and burning of waste—including pharmaceutical products—remain common, releasing harmful pollutants into the air and leaching chemicals into soil and water sources. Informal waste pickers may also come into contact with discarded medicines, posing a health risk to themselves and others through secondary exposure or inadvertent reuse. Additionally, counterfeit and substandard medications, once discarded, can re-enter the market in such informal economies, perpetuating cycles of harm (Kettle, *et al*., 2014; Daughton & Ruhoy, 2011). Bain, 2010 presented five main target areas for reducing environmental exposure to pharmaceutical waste based on the life cycle of pharmaceuticals shown in figure 4.



Fig 4: Five main target areas for reducing environmental exposure to pharmaceutical waste based on the life cycle of pharmaceuticals (Bain, 2010).

Technological advancements in drug formulation, including controlled-release medications and complex biological drugs, have introduced compounds that are more persistent in the environment. These substances resist degradation and accumulate over time, increasing ecological risks. Such concerns are not limited to human medicines alone;

veterinary drugs used for pets and livestock, although technically falling outside the narrow definition of post-consumer household waste, also contribute to the pharmaceutical load in the environment when improperly discarded (Singh & Yeh, 2017).

Pharmaceutical packaging materials—such as blister packs, plastic bottles, and syringes—add another layer of complexity to the waste stream. While these are often disposed of with regular household waste, they may contain drug residues that contribute to environmental contamination. In some countries, pharmaceutical packaging is classified as hazardous waste, but the enforcement of these classifications is inconsistent.

In conclusion, the sources and types of post-consumer pharmaceutical waste are diverse and rooted in everyday household behaviors, systemic inefficiencies, and a lack of regulatory standardization. The increasing availability and consumption of both prescription and OTC drugs have led to a steady rise in pharmaceutical residues entering the environment. Without widespread public education, clear disposal guidelines, and easily accessible take-back infrastructure, the improper handling of pharmaceutical waste will continue to pose serious challenges. To address this multifaceted issue, a deeper understanding of user behaviors, drug categories, and disposal pathways is essential. Only through an integrated approach—one that considers education, regulation, and technological innovation—can sustainable management of post-consumer pharmaceutical waste be achieved for the benefit of environmental and public health.

2.2 Environmental and Health Impacts of Improper Disposal

The improper disposal of post-consumer pharmaceutical waste has far-reaching environmental and health consequences that are increasingly being recognized as a global concern. As household pharmaceuticals continue to enter the environment through waste streams not designed for hazardous substances, the persistence of active pharmaceutical ingredients (APIs) in water bodies and soil raises significant alarms. When consumers flush unused or expired medications down toilets or sinks, or discard them in regular trash that ends up in landfills, these pharmaceutical residues bypass standard waste treatment systems and infiltrate natural ecosystems. The resulting contamination affects not only aquatic and terrestrial environments but also human health through direct and indirect exposure.

Water contamination is one of the most pressing issues associated with improper pharmaceutical disposal. Wastewater treatment plants, although efficient at removing conventional pollutants, are largely ineffective at eliminating pharmaceutical compounds due to the complexity and chemical stability of many APIs. These substances survive the treatment process and are subsequently discharged into rivers, lakes, and oceans. Studies around the world have detected measurable concentrations of analgesics, antibiotics, antidepressants, hormones, and other drug residues in surface and groundwater (Khan, *et al*., 2021, Slaughter, *et al*., 2019). This persistent contamination not only undermines water quality but also threatens drinking water supplies, particularly in regions where advanced filtration systems are unavailable. In some cases, treated wastewater is reused for agricultural irrigation or even potable use, further increasing the likelihood of human exposure to pharmaceutical pollutants.

The soil is similarly impacted by the leaching of pharmaceutical compounds from improperly disposed waste in landfills. When medications are thrown into household garbage, they are transported to municipal landfills where they may be subjected to leachate formation—liquid runoff that can carry soluble pharmaceutical residues into surrounding soil and groundwater. Over time, this contamination can degrade soil quality, reduce microbial diversity, and impair the fertility of agricultural lands. Pharmaceuticals like hormones and endocrine-disrupting compounds have been shown to persist in soil environments, influencing plant growth and soil organism behavior (Daughton & Ruhoy, 2013; Slaughter, *et al*., 2019).

One of the most dangerous consequences of pharmaceutical contamination in the environment is the emergence and proliferation of antimicrobial resistance (AMR). When antibiotics are discarded into the environment through wastewater or solid waste, they exert selective pressure on microbial populations, encouraging the survival and propagation of drug-resistant strains. These resistant microorganisms can exchange genetic material with other bacteria, spreading resistance genes across ecosystems and into human and animal pathogens (Thongsamer, *et al*., 2021). This phenomenon represents a serious global health threat, as it compromises the effectiveness of antibiotics used in clinical settings and undermines public health efforts to control infectious diseases. Environmental reservoirs of antibiotic resistance genes—especially in rivers near urban or industrial areas—are now considered significant contributors to the global AMR crisis.

The presence of trace antibiotics in aquatic environments has been linked to the emergence of resistant bacteria in fish, amphibians, and other aquatic organisms. These organisms may act as vectors for resistant microbes, facilitating their movement through the food web and potentially back to humans. Moreover, the spread of AMR through environmental channels often goes undetected until it reaches clinical relevance, making it a silent but dangerous contributor to antibiotic treatment failures and hospital-acquired infections (Khor, 2019, Truong, *et al*., 2021).

Bioaccumulation and the toxicological effects of pharmaceuticals on aquatic life and ecosystems present additional risks. Many pharmaceutical compounds, once introduced into water bodies, are absorbed by aquatic organisms such as fish, mollusks, and crustaceans. These substances can accumulate in tissues over time, leading to sub-lethal or lethal effects that disrupt physiological processes and behaviors. For instance, exposure to synthetic estrogens from birth control pills has been shown to cause feminization in male fish, impairing reproductive functions and threatening population stability (Daughton & Ruhoy, 2011; Verlicchi, *et al*., 2012). Antidepressants in water can alter the behavior and predator responses of fish, while anti-inflammatory drugs like diclofenac have been linked to kidney damage and mass die-offs in scavenger bird species feeding on contaminated carcasses.

The ecological consequences of pharmaceutical pollution are often subtle but cumulative. Chronic exposure to low concentrations of multiple pharmaceuticals can produce synergistic effects, where combined toxicity exceeds the effect of each substance in isolation. These impacts can cascade through food webs, disrupting predator-prey relationships, altering species composition, and reducing biodiversity. Sensitive species may be eliminated from affected ecosystems, allowing more tolerant but ecologically less valuable species to dominate, ultimately degrading ecosystem services (de Campos, Ten Caten & de Paula, 2021).

Moreover, the impact on non-target organisms extends beyond aquatic environments. Terrestrial wildlife, such as scavengers and small mammals, may ingest pharmaceuticals through contaminated water or food sources. In rural and peri-urban areas, domesticated animals may also come into contact with improperly disposed human medications, risking unintentional poisoning or disruption of physiological functions. The persistence of pharmaceuticals in the environment means that once contamination occurs, remediation is costly, time-consuming, and often incomplete (Kong, *et al*., 2017, Wang & Zhuan, 2020).

Human health is indirectly affected through these environmental pathways. Individuals relying on contaminated water sources, especially in regions lacking robust purification systems, may ingest trace amounts of pharmaceuticals daily. While individual exposure levels may be low, the chronic ingestion of multiple compounds over time has uncertain health implications. Vulnerable populations such as infants, pregnant women, the elderly, and immunocompromised individuals are at greater risk of adverse health outcomes from long-term low-level exposure. Moreover, the potential for endocrine disruption, developmental abnormalities, and immunological effects due to pharmaceutical residues cannot be ignored (de Oliveira Neto, Silva & Machado Santos, 2019; Wang, *et al*., 2016).

Another concern is the psychosocial and economic burden that environmental pharmaceutical pollution imposes on communities. Fear of water contamination can erode public trust in drinking water systems, leading to increased reliance on bottled water and greater economic expenditure for already disadvantaged populations. Ecosystem degradation also undermines livelihoods, especially in communities dependent on fishing, farming, or tourism, by reducing natural resource availability and biodiversity (Desai, Njoku & Nimo-Sefah, 2022).

Efforts to mitigate these environmental and health risks must prioritize a sustainable management strategy that includes proper disposal practices, regulatory reform, and public education. Encouraging pharmaceutical take-back programs, integrating green chemistry principles in drug design, and upgrading wastewater treatment technologies are essential steps toward minimizing the release of pharmaceutical contaminants. However, these interventions will only be effective if they are supported by widespread behavioral change and a holistic understanding of the interconnectedness of environmental and human health (Kotwani, Joshi & Kaloni, 2021).

In conclusion, the improper disposal of post-consumer pharmaceutical waste has profound implications for environmental quality and public health. Contamination of water bodies and soil, the acceleration of antimicrobial resistance, and the toxic effects of pharmaceutical bioaccumulation in aquatic and terrestrial ecosystems collectively represent a complex, multidimensional threat. These impacts are not isolated; they interact and reinforce each other, creating a cycle of ecological degradation and health vulnerability. Addressing these challenges requires coordinated action across sectors and borders, rooted in science-based policy, community engagement, and long-term environmental stewardship. Only through sustainable management practices can we mitigate the harm caused by pharmaceutical pollution and protect both planetary and human well-being for future generations.

2.3 Overview of International Take-Back Programs

International take-back programs for post-consumer pharmaceutical waste represent a critical component of sustainable waste management strategies, designed to curb the environmental and public health hazards associated with improper drug disposal. These programs are structured to provide the public with safe, convenient, and responsible means of discarding unused, expired, or leftover medications. Around the world, take-back initiatives have been implemented through a variety of models—pharmacy-based drop-offs, dedicated collection points, and mail-back systems—each tailored to the regulatory, cultural, and infrastructural context of its region. This section offers an in-depth overview of international pharmaceutical take-back programs, highlighting regional approaches, operational models, and key outcomes in terms of effectiveness, challenges, and public engagement.

In North America, the United States has established a nationally coordinated approach to pharmaceutical take-back under the leadership of the Drug Enforcement Administration (DEA). The DEA National Prescription Drug Take-Back Initiative is one of the most visible and organized efforts globally, offering periodic events where individuals can return unused prescription drugs anonymously (Eckstein, 2015). This initiative is supported by law enforcement agencies, community organizations, and healthcare providers, ensuring widespread coverage and accessibility. In addition to these events, the U.S. has authorized pharmacies and hospitals to operate as year-round collection sites under the Secure and Responsible Drug Disposal Act of 2010. Drop boxes and mail-back envelopes are distributed in communities, making the process more convenient for consumers (Ehrhart, *et al*., 2020). Despite these advances, public awareness remains a challenge. While millions of pounds of medications have been collected since the program's inception, studies show that a significant portion of the population is still unaware of these disposal options or uncertain about how to use them.

Canada has implemented a similar take-back system through its Medication Return Program, managed at the provincial level in collaboration with the Health Products Stewardship Association. This program enables consumers to return unused medications to participating pharmacies, often without the need for packaging or identification. The program’s decentralized nature allows provinces to design systems that reflect their unique needs and capacities, with most pharmacies in British Columbia, Ontario, and Quebec offering in-store return services (Krzemiński & Popowska, 2020). Public participation has steadily improved through education campaigns and pharmacy-led outreach, although rural access and funding constraints remain persistent barriers.

In Europe, several countries have adopted highly efficient pharmaceutical take-back programs, with Sweden often cited as a global model. The Swedish system integrates medication returns into the national healthcare and pharmacy infrastructure, allowing consumers to return unused drugs directly to any pharmacy at any time. The government mandates pharmacies to accept returned medications and ensures that all collected waste is transported for high-temperature incineration, minimizing environmental risks (Fenta, 2017). This streamlined process, supported by strong regulatory enforcement and consistent public messaging, has led to high participation rates and broad societal acceptance.

Germany and France have also made significant strides in pharmaceutical waste management. In Germany, take-back is embedded within the broader waste management framework under the "producer responsibility" principle. Consumers return unused medications to pharmacies, which then ensure appropriate disposal in line with hazardous waste regulations. The program benefits from strong collaboration among municipalities, pharmacies, and pharmaceutical companies. In France, the Cyclamed initiative collects and destroys unused medications through a centralized system managed by pharmaceutical manufacturers. Participation in Cyclamed is voluntary for consumers but widely encouraged through educational campaigns and visible collection containers in pharmacies. Public trust and awareness are key factors driving the success of such European models, where environmental consciousness is relatively high (Fidora, 2017).

Asia-Pacific countries display a more varied landscape, reflecting a mix of developed and developing contexts. In Australia, the Return Unwanted Medicines (RUM) Project allows consumers to return expired or unused medicines to pharmacies at no cost. The RUM Project is funded by the federal government and works in partnership with pharmacists to ensure that collected waste is safely destroyed by incineration (Freitas & Radis-Baptista, 2021). Despite its success in urban centers, outreach remains limited in remote communities, highlighting the need for inclusive policy design.

In contrast, many developing nations in Asia and Africa face substantial challenges in implementing effective pharmaceutical take-back programs. Infrastructure limitations, low public awareness, and competing health priorities often hinder the establishment of formal waste return systems. In countries such as India, Nigeria, and the Philippines, unused medications are often disposed of in household trash or through informal methods, such as open burning or sewer dumping. While pilot initiatives led by NGOs or international development agencies have shown promise, scaling up these programs requires institutional support, regulatory frameworks, and community engagement strategies (Gutberlet, 2016; Kumar & Pal, 2018). Moreover, cultural perceptions about waste, medication sharing, and environmental responsibility significantly influence public participation in such regions.

Implementation models for pharmaceutical take-back programs generally fall into three categories: pharmacy-based returns, drop-off points, and mail-back systems. Pharmacy-based models are the most common and effective, leveraging existing healthcare infrastructure and the trust consumers place in pharmacists. Pharmacies serve as accessible collection hubs, often without requiring extensive additional investment. Drop-off points, including public buildings, hospitals, and law enforcement offices, provide additional locations for medication returns, particularly during special collection events (Imad, *et al*., 2017; Landecker, 2016). Mail-back systems offer the convenience of returning medications using pre-paid envelopes, especially useful for individuals with limited mobility or in geographically dispersed communities. However, this model involves higher logistical costs and security concerns related to controlled substances.

The effectiveness of these take-back programs is closely tied to public participation rates and the volume of pharmaceuticals collected. Countries with robust public education campaigns, transparent disposal processes, and institutional collaboration tend to report higher return volumes and stronger user engagement. Sweden, for instance, reports over 70% public participation, while the U.S. DEA program has collected more than 15 million pounds of medication since its inception. On the other hand, limited awareness, lack of incentives, and privacy concerns can significantly reduce user participation, even in well-resourced systems (Jjemba, 2018). For example, some consumers are hesitant to return medications due to concerns about judgment, cost, or uncertainty over what items are accepted.

Challenges to program implementation include funding constraints, regulatory fragmentation, lack of standardized practices, and limited access in rural or underserved areas. Additionally, measuring the actual environmental impact of these programs is complex, as comprehensive data on pharmaceutical pollution reduction remains limited. Integration with broader sustainability goals, such as green pharmacy initiatives and circular economy models, is also underexplored in many regions (King, Hutchinson & Boxall, 2021).

In summary, international take-back programs for post-consumer pharmaceutical waste offer a range of implementation strategies and outcomes. Countries like the U.S., Sweden, and Germany demonstrate how regulatory commitment, public awareness, and convenient infrastructure can combine to create effective systems. Meanwhile, developing nations face unique barriers that must be addressed through tailored policies, education, and capacity-building. While pharmacy-based models dominate due to their accessibility and trust factor, drop-off and mail-back systems offer valuable alternatives. The effectiveness of any model ultimately depends on how well it engages users, integrates with health and environmental systems, and adapts to local contexts. Strengthening these programs globally will require a collaborative and adaptive approach that balances innovation, education, and equity in pharmaceutical waste management.

2.4 Regulatory and Policy Frameworks

The regulatory and policy frameworks governing the sustainable management of post-consumer pharmaceutical waste form the foundation for effective take-back programs and environmentally safe disposal methods. These frameworks are vital in shaping the responsibilities of pharmaceutical manufacturers, healthcare providers, pharmacies, and consumers, ensuring that unused and expired medications are collected and disposed of without harming the environment or public health (Kurniawan, *et al*., 2022). Despite global efforts to standardize and promote pharmaceutical waste management, there exists a significant disparity between developed and developing nations in terms of regulatory strength, enforcement capacity, and public compliance. This disparity has far-reaching implications for environmental protection and sustainable development.

At the global level, the World Health Organization (WHO) has played a pivotal role in establishing broad guidelines and promoting international best practices for pharmaceutical waste management. The WHO's recommendations emphasize the need for safe disposal methods that prevent the contamination of water sources, soil, and the food chain. These guidelines advocate for high-temperature incineration as the preferred method for destroying pharmaceutical waste, particularly for cytotoxic and controlled substances (Landecker, 2019). Where incineration is not feasible, the WHO proposes alternative containment and burial techniques, albeit with caution due to environmental limitations. Furthermore, WHO guidelines underscore the importance of public education, healthcare worker training, and integrated pharmaceutical supply chain oversight as components of sustainable waste management strategies. These recommendations serve as reference points for national policy formulation and have been adapted into various national and regional regulations.

In many high-income countries, regulatory frameworks on pharmaceutical waste have evolved significantly, driven by growing environmental awareness and public health concerns. In the United States, agencies such as the Food and Drug Administration (FDA), the Environmental Protection Agency (EPA), and the Drug Enforcement Administration (DEA) have collaborated to regulate the management of post-consumer medications. The Secure and Responsible Drug Disposal Act of 2010, in particular, marked a significant policy shift by allowing pharmacies and hospitals to serve as authorized collectors of controlled substances (Lago, Kolling & Auler, 2022; Luo, *et al*., 2021). The FDA also publishes regularly updated guidelines for consumers on how to dispose of medications safely when take-back options are unavailable, including a "flush list" for drugs that pose immediate risks if left unsecured. Moreover, the EPA regulates the environmental aspects of pharmaceutical disposal through the Resource Conservation and Recovery Act (RCRA), which classifies certain pharmaceuticals as hazardous waste, requiring specialized handling.

In the European Union, a comprehensive and harmonized regulatory framework is provided by the Waste Framework Directive (Directive 2008/98/EC) and the Directive on Hazardous Waste (Directive 91/689/EEC), which define pharmaceutical waste as a category of hazardous waste requiring controlled management. These directives are reinforced by the EU Directive 2001/83/EC on the Community Code relating to medicinal products for human use, which includes provisions on the collection and disposal of unused medicines (Le Quesne, *et al*., 2018; Mahmood, 2010). EU member states are required to implement take-back schemes at the national level, typically involving pharmacies as collection points. Countries like Sweden, France, and Germany have effectively integrated these directives into national law, supported by producer responsibility schemes that mandate pharmaceutical companies to finance or facilitate the safe collection and disposal of unused medications. This approach not only promotes environmental sustainability but also ensures corporate accountability within the pharmaceutical supply chain.

Despite the existence of these robust regulatory frameworks in developed regions, a significant regulatory and enforcement gap remains in many developing countries. These nations often lack dedicated laws on pharmaceutical waste or include it only tangentially within broader waste management policies. In some cases, regulatory responsibilities are fragmented across multiple government departments with poor coordination, resulting in ineffective implementation. While certain countries have adopted environmental protection laws or health regulations that indirectly cover pharmaceutical waste, enforcement is often hampered by limited institutional capacity, lack of funding, and absence of technical infrastructure for safe disposal (Le Roux, *et al*., 2011; Makki, *et al*., 2019).

For instance, in parts of sub-Saharan Africa, Southeast Asia, and Latin America, pharmaceutical waste from households is commonly mixed with general solid waste, which is then dumped in open landfills, rivers, or burned in uncontrolled conditions. The absence of well-defined regulations and enforcement mechanisms allows these practices to persist, exposing communities to hazardous substances and increasing the risk of environmental contamination (Lees, 2021). Additionally, weak regulatory oversight allows expired medications to be recycled back into informal markets, particularly in regions where counterfeit drugs and unregulated drug sales are prevalent. This not only endangers public health but also undermines the integrity of healthcare systems (Li, *et al*., 2011; Mallick, *et al*., 2022).

Another major regulatory challenge in developing countries is the lack of clarity on the roles and responsibilities of stakeholders involved in pharmaceutical waste management. Unlike the extended producer responsibility (EPR) models found in the EU, many low-income countries have not assigned financial or logistical responsibilities to pharmaceutical manufacturers. Consequently, the burden of managing pharmaceutical waste often falls on under-resourced public health institutions and municipalities, which may lack the expertise or infrastructure for safe collection and disposal. In the absence of incentives or legal mandates, pharmacies and healthcare providers are also unlikely to voluntarily participate in take-back initiatives, further limiting public access to safe disposal options (Mitkidis, *et al*., 2021).

In addition to institutional gaps, cultural and behavioral factors contribute to low compliance with safe disposal guidelines in developing regions. Public awareness of the environmental and health risks of improper pharmaceutical disposal is often limited, and there is minimal outreach or education to change disposal habits. Without sustained communication campaigns and community engagement, even well-intentioned regulations are unlikely to achieve meaningful compliance. Moreover, where regulations do exist, they are often not enforced consistently due to weak monitoring systems, corruption, or political instability. This undermines public trust in environmental and health governance and diminishes the perceived importance of pharmaceutical waste regulation (Li, *et al*., 2021; Musee, 2011).

To address these regulatory and policy deficiencies, international cooperation and technical assistance are essential. Development partners, including the WHO, United Nations Environment Programme (UNEP), and bilateral donors, have a crucial role to play in supporting the development and enforcement of pharmaceutical waste regulations in low- and middle-income countries. This support can take the form of funding for pilot projects, training for regulatory agencies, infrastructure development, and the sharing of best practices. In addition, integrating pharmaceutical waste management into broader national strategies on healthcare, water and sanitation, and climate change can improve coherence and mobilize cross-sectoral support (Li, 2014; Muth, *et al*., 2019).

In conclusion, the regulatory and policy frameworks for the sustainable management of post-consumer pharmaceutical waste vary widely across countries and regions, reflecting differences in institutional capacity, public awareness, and political will. While the WHO and other international organizations provide comprehensive guidelines and promote best practices, their implementation remains uneven. Developed countries, through agencies like the U.S. FDA and the European Commission, have established robust laws and systems that have significantly improved pharmaceutical waste management (Lima, Domingues & Da Silva, 2020). However, developing countries continue to struggle with regulatory fragmentation, enforcement challenges, and resource constraints. Bridging this gap requires not only national commitment but also international collaboration, public-private partnerships, and grassroots engagement. Ultimately, effective regulation is the backbone of sustainable pharmaceutical waste management and is critical to safeguarding environmental and public health on a global scale.

2.5 Advanced Disposal Technologies

Advanced disposal technologies play a pivotal role in the sustainable management of post-consumer pharmaceutical waste. As pharmaceutical consumption increases globally, conventional waste disposal methods such as open burning, landfill dumping, and uncontrolled incineration are no longer adequate or environmentally safe. Instead, a transition toward sophisticated and scientifically validated disposal methods is essential to reduce environmental contamination, mitigate health risks, and promote circular waste economies. The implementation of these advanced technologies offers a path toward environmental protection and long-term sustainability by addressing the complexity and persistence of active pharmaceutical ingredients (APIs) in waste streams (Muthuraman & Ramaswamy, 2019). Several technologies have emerged as effective solutions, each with its own advantages and limitations in terms of efficiency, environmental safety, and economic feasibility.

Incineration remains one of the most widely adopted disposal technologies for pharmaceutical waste, particularly in high-income countries. High-temperature incineration, often conducted at temperatures exceeding 1,000°C, is highly effective in breaking down complex chemical compounds found in medications. Controlled incineration facilities equipped with advanced emission control systems can minimize the release of harmful pollutants such as dioxins, furans, and heavy metals (Lofrano, *et al*., 2017; Nciri, Kim & Caron, 2022). These facilities are designed to ensure complete combustion, reducing pharmaceuticals to harmless residues while adhering to stringent environmental standards. Incineration is considered a best available technique (BAT) under European Union guidelines and is endorsed by the World Health Organization for the disposal of hazardous medical and pharmaceutical waste.

However, despite its proven efficacy, incineration faces several challenges. It requires significant infrastructure investment, skilled operation, and continuous monitoring to meet environmental standards. Improperly operated incinerators or low-tech versions in developing countries can emit toxic by-products, negating environmental benefits. Furthermore, the high energy demand of incineration raises concerns about its carbon footprint and long-term sustainability, especially in regions pursuing low-emission development pathways. While incineration remains indispensable for high-risk pharmaceutical waste, it is not always economically or environmentally optimal for general post-consumer medications (Nyaga, Nyagah & Njagi, 2020).

An alternative to incineration gaining attention is plasma gasification, a high-temperature thermal process that uses an electric arc or plasma torch to ionize gas and convert waste into a synthetic gas (syngas) and an inert vitrified slag. Unlike incineration, which combusts waste in the presence of oxygen, plasma gasification operates in a low-oxygen environment, reducing the formation of harmful emissions and enabling better control over the chemical reactions. Pyrolysis, a related process, thermally decomposes organic material in the absence of oxygen, producing syngas, bio-oil, and char (Luongo, *et al*., 2020; Ongondo, Williams & Cherrett, 2011). These technologies not only destroy hazardous pharmaceutical compounds but also produce potentially useful by-products that can be utilized for energy generation or material recovery.

Both plasma gasification and pyrolysis are considered cleaner alternatives to incineration, particularly in terms of emission profiles. They have demonstrated the capacity to degrade persistent pharmaceutical compounds and minimize environmental toxicity. However, the economic feasibility of these technologies remains a key constraint. Capital and operational costs are significantly higher than traditional methods, and the technologies require a continuous, homogenous waste feed to function efficiently (Oppong & Phiri, 2018). Furthermore, their deployment is largely limited to industrialized countries or regions with strong institutional support and advanced waste management infrastructure. For most developing nations, such technologies are currently cost-prohibitive without external funding or public-private partnerships.

Chemical deactivation systems represent another category of pharmaceutical disposal technologies, particularly suited for decentralized, small-scale applications such as hospitals, pharmacies, and even households. These systems typically use chemical agents to render active pharmaceutical ingredients inert by altering their molecular structure. Commercial products have been developed that allow users to add water and a proprietary substance to a medication container, initiating a reaction that neutralizes the drug. Once deactivated, the mixture can be safely discarded in regular household waste (Manyi-Loh, *et al*., 2018; Patel, *et al*., 2021). This method is particularly useful for opioids and controlled substances, providing a secure, user-friendly way to prevent diversion or misuse.

The advantages of chemical deactivation lie in its accessibility, simplicity, and relatively low cost. It offers a practical solution for facilities without access to high-temperature treatment or formal take-back programs. Additionally, the technology helps address the social issue of unused medications being diverted for recreational use. However, questions remain about the environmental safety of deactivation by-products and the disposal of the resulting waste. While these systems claim to produce non-toxic residues, long-term studies on the ecological impact of these by-products are limited (Paut Kusturica, Tomas & Sabo, 2017). Regulatory agencies are beginning to develop standards to evaluate the efficacy and safety of chemical deactivation systems, but widespread adoption will depend on clear guidance and public trust.

Emerging green disposal innovations are introducing more sustainable and environmentally benign methods for handling pharmaceutical waste. Among these, enzymatic degradation and bioreactor-based treatment systems hold significant promise. Enzymatic degradation employs specially designed enzymes to break down pharmaceutical compounds into harmless substances. This approach is still largely in the research and pilot stage but has demonstrated potential for applications in wastewater treatment plants and pharmaceutical manufacturing facilities (Marican & Durán-Lara, 2018). Unlike thermal or chemical methods, enzymatic processes occur under mild conditions and produce minimal secondary pollutants.

Bioreactors, often coupled with microbial communities engineered to target specific APIs, are another frontier in pharmaceutical waste treatment. These systems use biological processes to degrade pharmaceuticals in aqueous environments, making them particularly suitable for treating wastewater contaminated with drug residues. Advances in biotechnology have led to the development of bioaugmentation strategies, in which specific microbial strains are introduced to enhance degradation performance (Pereira, de Vasconcelos Barros & Pereira, 2017). These innovations could revolutionize pharmaceutical waste management by providing low-energy, scalable, and eco-friendly alternatives to traditional methods.

Despite their potential, green disposal technologies face several barriers to adoption. They require further research to optimize degradation rates, ensure broad-spectrum efficacy, and validate environmental safety. Moreover, scalability and economic feasibility remain uncertain, especially in resource-constrained settings. Investment in research and development, supported by policy incentives and international collaboration, will be essential to transition these technologies from laboratory prototypes to commercially viable solutions (Mazivila, *et al*., 2019; Rogowska & Zimmermann, 2022).

In assessing the overall efficiency, environmental safety, and economic feasibility of advanced disposal technologies, no single method emerges as universally superior. High-temperature incineration remains effective for hazardous waste but poses sustainability concerns. Plasma gasification and pyrolysis offer cleaner emission profiles but are capital-intensive. Chemical deactivation provides a decentralized solution with social benefits but raises questions about residual safety. Emerging green innovations show long-term promise but require more development and validation. An integrated approach that combines these technologies based on waste type, available infrastructure, and regional context is the most practical path forward (McCarthy, *et al*., 2021; Shi, Petruzzi & Chhajed, 2022).

Ultimately, the adoption of advanced disposal technologies must be supported by a robust policy framework, cross-sectoral collaboration, and sustained public education. Stakeholders—including governments, healthcare providers, pharmaceutical companies, and environmental agencies—must work together to ensure that the chosen technologies align with local needs, environmental goals, and financial realities. Sustainable management of post-consumer pharmaceutical waste will not only mitigate pollution and safeguard public health but also support the transition toward a circular economy in the healthcare sector. Continued innovation, responsible regulation, and community engagement are vital to realizing the full potential of advanced disposal technologies for pharmaceutical waste.

2.6 Comparative Analysis of Take-Back vs. Disposal Technologies

A comparative analysis of pharmaceutical take-back programs and advanced disposal technologies reveals both approaches as essential yet distinct strategies in the sustainable management of post-consumer pharmaceutical waste. Each approach brings specific strengths and limitations, and their effectiveness is shaped by how well they are integrated into broader systems, including circular economy models and public education efforts. The growing urgency to address environmental contamination, public health threats, and the inefficiencies of traditional waste management calls for a clear understanding of how take-back and disposal mechanisms function independently and how they can complement each other within a sustainable waste management framework.

Take-back programs are fundamentally designed to intercept post-consumer pharmaceutical waste at the source, offering the public safe and convenient options for returning expired, unused, or leftover medications. These programs typically operate through pharmacy-based returns, secure drop-off locations, or mail-back systems, ensuring that drugs are collected before they can be improperly discarded (Merker, *et al*., 2020; Stoddard & Huggett, 2012). The core strength of take-back programs lies in their potential to prevent environmental pollution and reduce risks related to accidental poisoning, drug diversion, and misuse. They also promote shared responsibility among consumers, healthcare providers, and pharmaceutical companies by encouraging ethical and transparent end-of-life drug practices.

One of the greatest advantages of take-back initiatives is their accessibility. When effectively implemented, they provide a decentralized infrastructure that empowers communities to participate actively in pharmaceutical waste management. Countries such as Sweden, Canada, and the United States have shown that sustained public engagement in take-back schemes can significantly reduce the volume of pharmaceuticals entering landfills or water systems (Thane, 2021; Vatovec, *et al*., 2021). These programs also offer a platform for embedding public health messages, allowing governments to educate citizens about the risks of improper drug disposal and the importance of medication adherence and storage.

However, take-back programs also have inherent limitations. Their success is heavily dependent on public participation, which in turn relies on awareness, convenience, and trust in the system. In many countries, especially in rural and under-resourced areas, access to collection points is limited, and citizens may lack knowledge about available disposal options. Operational challenges such as inconsistent funding, regulatory gaps, and lack of standardization across jurisdictions further impede the reach and impact of take-back programs (Mohapatra, *et al*., 2014). Moreover, while take-back schemes effectively divert pharmaceuticals from unsafe disposal channels, they do not themselves neutralize the waste. Instead, they require downstream integration with appropriate treatment or destruction technologies to ensure environmental safety.

In contrast, advanced disposal technologies are engineered to address the end-of-life treatment of pharmaceutical waste, offering scientifically robust methods for the destruction or neutralization of active pharmaceutical ingredients (APIs).

These include high-temperature incineration, plasma gasification, chemical deactivation systems, and emerging green methods such as enzymatic degradation and bioreactors. These technologies provide direct environmental protection by reducing pharmaceutical pollutants to inert or less harmful compounds (Monapathi, *et al*., 2021; Vatovec, Van Wagoner & Evans, 2017). The greatest strength of advanced disposal methods lies in their ability to break down complex chemical structures that persist in natural environments and wastewater systems.

High-temperature incineration, for instance, remains the gold standard for hazardous pharmaceutical waste, capable of achieving complete thermal destruction of most drug compounds. Plasma gasification and pyrolysis offer improved emission profiles, converting pharmaceutical waste into syngas and inert slag with lower environmental impact. Chemical deactivation systems bring convenience and security for decentralized applications, particularly for opioid and controlled substance disposal. Meanwhile, bioreactors and enzymatic treatments hold promise for the long-term shift toward more environmentally friendly, energy-efficient disposal options.

Nonetheless, advanced disposal technologies are not without drawbacks. High infrastructure costs, energy consumption, and technical complexity make these systems less accessible in many low- and middle-income countries. Improperly managed incineration can release toxic by-products, and newer technologies like plasma gasification and enzymatic degradation require further validation, standardization, and economic modeling before widespread adoption (Nagarnaik, Batt & Boulanger, 2012). Additionally, most advanced disposal solutions are downstream interventions; they address pharmaceutical pollution only after waste has been collected, which limits their preventative potential.

When considering the integration of both approaches into circular economy models, take-back programs offer a strategic entry point for material recovery, stakeholder engagement, and lifecycle accountability. In a circular economy, resources are used efficiently, waste is minimized, and products are designed with end-of-life recovery in mind. Take-back programs can act as the bridge between pharmaceutical consumers and the larger sustainability goals of the healthcare and pharmaceutical industries (Nguyen, *et al*., 2021). They facilitate traceability and help build systems that prioritize waste reduction, responsible production, and extended producer responsibility.

However, achieving circularity in pharmaceutical waste management is uniquely challenging. Unlike materials such as plastic or metal, most pharmaceutical compounds are not suitable for reuse or recycling due to safety, efficacy, and contamination concerns. As such, the circular model in this context must focus more on safe loop closure through responsible collection, reduction at the source, green drug design, and effective destruction. Advanced disposal technologies, while inherently linear in operation, are still vital in supporting circularity by ensuring that pharmaceutical waste does not accumulate in ecosystems, thus preserving environmental integrity for future production cycles (Ojemaye & Petrik, 2019).

Public education and awareness are crucial in complementing both take-back programs and disposal technologies. Without informed and motivated public participation, even the most sophisticated systems can fail to achieve their objectives. Education campaigns that explain the environmental and health risks of improper pharmaceutical disposal can drive behavioral change, boost participation in take-back schemes, and foster public support for investment in disposal infrastructure. Furthermore, educating healthcare professionals, pharmacists, and policy-makers about safe disposal methods ensures that consistent, credible information reaches consumers.

An effective public awareness strategy should include clear guidance on what types of drugs can be returned or deactivated, how to access disposal services, and the broader implications of pharmaceutical pollution. Messaging must be culturally sensitive, accessible, and reinforced through various channels, including community outreach, media campaigns, school programs, and digital platforms. The involvement of trusted local figures, such as pharmacists and physicians, is essential to building trust and ensuring that education efforts resonate with the public (Oliveira, Al Aukidy & Verlicchi, 2018).

In summary, both take-back programs and advanced disposal technologies serve indispensable but complementary roles in the sustainable management of post-consumer pharmaceutical waste. Take-back programs emphasize prevention and participation, collecting medications before they cause harm. Disposal technologies ensure the safe and environmentally responsible elimination of collected waste. Together, they form a dual mechanism that can significantly reduce pharmaceutical pollution and safeguard public health when integrated into a coherent policy and operational framework.

To maximize the impact of these systems, governments and stakeholders must pursue synergistic strategies that link upstream collection with downstream treatment, support innovation in green technologies, and promote widespread public education. Moreover, a shift toward circular economy thinking can further enhance sustainability by embedding pharmaceutical waste management within a broader vision of responsible consumption, environmental protection, and systemic accountability. Ultimately, the success of any pharmaceutical waste strategy will depend not only on technical efficiency but also on societal engagement, policy coherence, and the global commitment to environmental health.

2.7 Global Trends and Best Practices

Global trends in the sustainable management of post-consumer pharmaceutical waste reflect a growing recognition of the urgent need to prevent environmental contamination, reduce public health risks, and foster more responsible consumption patterns. With increased pharmaceutical usage driven by rising populations, expanded healthcare access, and aging societies, managing the vast quantities of unused, expired, and leftover medications has become a priority for both developed and developing nations. Over the past two decades, governments, non-governmental organizations, the private sector, and communities have collaborated to establish and refine models for effective pharmaceutical waste management. The success of these initiatives varies by context but offers valuable lessons and best practices that can inform global efforts.

Successful case studies from countries with well-developed healthcare and waste management systems serve as benchmarks for global pharmaceutical waste control. Sweden, for example, is widely recognized for its efficient, nationwide pharmaceutical take-back program. The country mandates that all pharmacies accept unused medications, which are collected and incinerated under controlled, high-temperature conditions to prevent environmental harm. The program's effectiveness is attributed to its integration into the broader healthcare system, consistent regulatory enforcement, and robust public participation fostered by sustained public awareness campaigns (Oliveira, *et al*., 2015; Worrell & Reuter, 2014). The Swedish model demonstrates how policy, infrastructure, and community involvement can coalesce to form a highly functional waste management system.

In France, the Cyclamed program provides another exemplary case. Operated by a non-profit organization funded by pharmaceutical manufacturers, Cyclamed facilitates the return of unused household medications to pharmacies, where they are collected and incinerated in energy recovery facilities. Cyclamed has achieved considerable success through a public-private partnership approach that aligns industry responsibility with consumer behavior and environmental stewardship. It has also benefited from intensive public education efforts that use print, broadcast, and digital media to raise awareness about the dangers of improper medication disposal (Oluwole, Omotola & Olatunji, 2020).

Canada's Medication Return Programs, operated provincially and supported by the Health Products Stewardship Association, offer further insight into effective decentralized models. Each province tailors its take-back initiative to local needs while maintaining national consistency through harmonized public messaging and collection practices. In British Columbia, for example, the program includes not only pharmaceuticals but also natural health products and sharps, demonstrating an integrated approach to household health waste. Public trust in pharmacies and ongoing collaboration between healthcare providers and environmental agencies have made this model effective and sustainable (Ort, *et al*., 2010; Xie & Breen, 2014).

In the United States, the DEA's National Prescription Drug Take Back Day provides an annual opportunity for the safe disposal of medications. While not a continuous program, the event has collected millions of pounds of unused drugs, raising awareness and reducing the risk of substance abuse. Complementary permanent take-back kiosks in pharmacies and health centers now support year-round disposal, and some states have launched their own drug stewardship laws requiring pharmaceutical companies to fund the collection and disposal of post-consumer drugs.

The involvement of the private sector, particularly pharmaceutical manufacturers and retail pharmacy chains, has been a critical factor in scaling sustainable waste management solutions. Public-private partnerships (PPPs) have proven to be a powerful mechanism for aligning commercial interests with environmental and public health objectives. Pharmaceutical companies are increasingly participating in extended producer responsibility (EPR) schemes, where they assume financial or logistical responsibility for the end-of-life management of their products (Pikkemaat, *et al*., 2016). These partnerships not only share the economic burden of waste management but also encourage innovation in drug formulation, packaging, and eco-design.

Retail pharmacy chains in many countries have taken proactive steps by offering medication disposal services. In the U.S., major chains such as CVS and Walgreens have installed take-back bins in thousands of locations, providing easy and safe access for consumers. In Australia, the Return Unwanted Medicines (RUM) project partners with local pharmacies and the government to ensure collected medicines are destroyed via high-temperature incineration. These partnerships illustrate how the private sector can contribute critical infrastructure, customer access points, and financial resources to support public waste management goals (Postigo & Richardson, 2014).

Community engagement and public education remain the linchpins of any successful pharmaceutical waste initiative. Even the most well-funded and technologically advanced programs will fail without public awareness and participation. Globally, education campaigns have emerged as key components of pharmaceutical waste strategies, informing consumers about the environmental risks of improper disposal and empowering them to take part in solutions. These campaigns use diverse methods, from mass media advertisements and social media outreach to school-based programs and grassroots initiatives led by community health workers.

In Japan, pharmaceutical waste education is integrated into broader environmental curricula, encouraging children and families to develop sustainable disposal habits from an early age. Educational materials explain the dangers of flushing medications or tossing them in household trash, emphasizing long-term consequences such as water pollution and antimicrobial resistance. In the Philippines and other parts of Southeast Asia, NGOs have collaborated with community health volunteers to deliver localized, culturally relevant messages that resonate with different population groups (Pruden, *et al*., 2013).

In Kenya and Nigeria, pilot projects supported by international development agencies have experimented with mobile app platforms and community radio broadcasts to spread awareness of safe medication disposal practices. These innovations address infrastructure limitations and leverage popular communication channels to reach rural and underserved communities. The projects have also engaged religious and traditional leaders to promote environmentally responsible behaviors, recognizing their influence and trust in local communities (Reid, 2020).

Best practices from these global experiences suggest that the most effective pharmaceutical waste management systems are those that combine several key elements: strong regulatory support, coordinated public-private partnerships, inclusive community engagement, and flexible implementation models. Programs must be designed to reflect local realities, including infrastructure, cultural norms, and health system capacity (Quintana, *et al*., 2010). While one-size-fits-all approaches are unlikely to succeed, adaptable frameworks grounded in evidence and participatory governance offer the best chance of achieving widespread impact.

Furthermore, innovation continues to shape future trends. Smart collection bins equipped with sensors and tracking technologies are being piloted in Europe to monitor return rates and streamline logistics. Green drug design—where medications are engineered to degrade more easily in the environment—is being explored by pharmaceutical researchers as a long-term strategy. Advances in artificial intelligence are also being used to optimize collection routes, forecast waste volumes, and personalize public awareness campaigns based on demographic data (Reggiane de

Carvalho Costa, Guerra Pacheco Nunes & Amaral Féris, 2021).

In conclusion, global trends in sustainable management of post-consumer pharmaceutical waste highlight a growing movement toward integrated, multi-stakeholder solutions that combine technological innovation, regulatory enforcement, and community empowerment. Successful case studies from Sweden, France, Canada, and Australia underscore the importance of aligning policy with practice, and of involving the private sector and civil society in every stage of waste management. As more countries recognize the environmental and health imperatives of addressing pharmaceutical pollution, the sharing of knowledge, funding, and best practices will be vital to global progress. Ultimately, the success of these initiatives depends not just on systems and structures but on the collective commitment of individuals, institutions, and industries to safeguard environmental health for current and future generations.

3. Conclusion and Recommendations for Sustainable Implementation

The sustainable management of post-consumer pharmaceutical waste has emerged as a global imperative, requiring coordinated efforts across sectors, borders, and communities. As highlighted throughout this assessment, improper disposal practices—ranging from flushing medications to discarding them in household trash—pose significant risks to environmental integrity, public health, and the effectiveness of modern medicine. Active pharmaceutical ingredients continue to contaminate water bodies and soil, contribute to the spread of antimicrobial resistance, and impact aquatic and terrestrial ecosystems through bioaccumulation. In response, a range of international take-back programs and advanced disposal technologies has been developed, with varying degrees of success based on governance, infrastructure, public engagement, and economic capacity.

Key insights from global experiences reveal that no single solution is sufficient to address the complex nature of pharmaceutical waste. Take-back programs excel at prevention and community engagement, offering accessible routes for safe collection and raising public awareness about environmental and health risks. However, their effectiveness is limited without seamless integration with environmentally sound disposal technologies. High-temperature incineration, plasma gasification, chemical deactivation, and emerging green innovations offer robust methods for neutralizing pharmaceutical compounds, yet they require consistent feedstock, technical expertise, and capital investment. The success of either system depends on the extent to which they are harmonized and embedded within broader national waste management and healthcare strategies.

To sustainably implement pharmaceutical waste management systems, there is an urgent need to harmonize take-back initiatives with technologically appropriate disposal methods. This harmonization demands not only regulatory alignment but also operational integration, wherein collected drugs are efficiently routed to certified treatment facilities. Policymakers should prioritize developing standard operating procedures that define roles for stakeholders across the value chain—from pharmaceutical manufacturers and healthcare providers to local waste handlers and environmental authorities. Regulations must ensure the safe treatment of pharmaceutical waste, incentivize eco-friendly product design, and require manufacturers to participate in extended producer responsibility schemes.

Equally important is capacity building and infrastructure development, particularly in low- and middle-income countries. Many of these nations struggle with inadequate waste treatment infrastructure, fragmented regulations, and limited technical capacity. Without targeted investments in treatment facilities, transportation systems, and staff training, take-back programs and disposal technologies cannot operate at scale or meet environmental safety standards. Governments, with support from international development agencies and the private sector, must allocate resources for the construction and maintenance of compliant treatment centers, the provision of mobile disposal units for rural areas, and the deployment of technologies that are contextually appropriate and environmentally sound.

Global cooperation is another critical enabler of sustainable implementation. Pharmaceutical pollution does not respect national borders; residues from improperly disposed medications can enter transboundary water systems and impact global ecosystems. It is therefore essential for nations to share data, innovations, and policy frameworks through multilateral platforms such as the World Health Organization, United Nations Environment Programme, and other regional bodies. The creation of international standards and monitoring protocols will foster accountability and allow for benchmarking progress. In addition, data-driven decision-making must be embedded in every stage of pharmaceutical waste management. This includes mapping pharmaceutical consumption trends, tracking return rates, monitoring environmental impacts, and evaluating the performance of disposal technologies. Reliable data allows governments and stakeholders to tailor interventions, optimize resource allocation, and continually improve waste management practices.

The urgency for global action cannot be overstated. The continued release of pharmaceuticals into the environment threatens to undermine public health advancements, disrupt ecosystems, and increase the burden of disease through drug-resistant pathogens. Rising medication use, coupled with population growth and expanding healthcare access, only intensifies the challenge. Countries must treat pharmaceutical waste management not as an optional environmental initiative but as an integral component of public health and sustainable development agendas. Failure to act will have cascading effects on biodiversity, food safety, and the resilience of health systems worldwide.

To safeguard both environmental and public health, integrative solutions are essential. This means breaking down silos between health, environment, and waste sectors and designing policies that reflect the interconnectedness of pharmaceutical production, consumption, and disposal. Governments should implement national strategies that combine education, regulation, infrastructure investment, and technological innovation. Private sector actors, including pharmaceutical companies and retailers, must be held accountable for product stewardship and incentivized to invest in green disposal solutions. Civil society organizations and communities must be empowered with knowledge and tools to take part in responsible disposal practices. Academic and research institutions can play a role in developing and validating new technologies, while international donors should support capacity-building programs and knowledge transfer.

In conclusion, sustainable management of post-consumer pharmaceutical waste requires a comprehensive and collaborative approach, one that harmonizes collection and treatment systems, builds capacity across all levels, and fosters global cooperation. The evidence is clear: isolated interventions are insufficient. Only through coordinated, integrative, and data-informed strategies can the world prevent further pharmaceutical pollution, protect ecosystems, and uphold the health and safety of current and future generations. The time to act is now, with commitment, innovation, and shared responsibility as the pillars of a cleaner and healthier future.

4. References

1. Ariffin M, Zakili TST. Household pharmaceutical waste disposal in Selangor, Malaysia—policy, public perception, and current practices. Environ Manage. 2019;64(4):509–19.
2. Bain KT. Public health implications of household pharmaceutical waste in the United States. Health Serv Insights. 2010;3:HSI-S4673.
3. Banjoko B. Environmental pharmacology–an overview. Pharmacol Ther. 2014.
4. Bashaar M, Thawani V, Hassali MA, Saleem F. Disposal practices of unused and expired pharmaceuticals among general public in Kabul. BMC Public Health. 2017;17:1–8.
5. Begum MM, Rivu SF, Hasan MMA, Nova TT, Rahman MM, Alim MA, *et al*. Disposal practices of unused and leftover medicines in the households of Dhaka metropolis. Pharmacy. 2021;9(2):103.
6. Benyam A. An interdisciplinary examination of behaviours and policy preferences for domestic food waste reduction: The case of households in Central Queensland, Australia [PhD thesis]. CQUniversity; 2019.
7. Bucknall DG. Plastics as a materials system in a circular economy. Philos Trans R Soc A. 2020;378(2176):20190268.
8. Carson KM. Networking to Sustainability: Analysis of a Collaboration to Address the "Wicked Problem" of Pharmaceutical Waste [PhD thesis]. Saint Louis University; 2018.
9. Chen HL, Nath TK, Chong S, Foo V, Gibbins C, Lechner AM. The plastic waste problem in Malaysia: management, recycling and disposal of local and global plastic waste. SN Appl Sci. 2021;3:1–15.
10. Chung SS, Brooks BW. Identifying household pharmaceutical waste characteristics and population behaviors in one of the most densely populated global cities. Resour Conserv Recycl. 2019;140:267–77.
11. Corcoran E. Sick water?: the central role of wastewater management in sustainable development: a rapid response assessment. UNEP/Earthprint; 2010.
12. Das KP, Sharma D, Saha S, Satapathy BK. From outbreak of COVID-19 to launching of vaccination drive: invigorating single-use plastics, mitigation strategies, and way forward. Environ Sci Pollut Res. 2021;28:55811–45.
13. Daughton CG. Drugs and the environment: stewardship & sustainability. US Environmental Protection Agency; 2010.
14. Daughton CG, Ruhoy IS. Green pharmacy and pharmEcovigilance: prescribing and the planet. Expert Rev Clin Pharmacol. 2011;4(2):211–32.
15. Daughton CG, Ruhoy IS. Lower-dose prescribing: minimizing “side effects” of pharmaceuticals on society and the environment. Sci Total Environ. 2013;443:324–37.
16. de Campos EAR, Ten Caten CS, de Paula IC. End-of-use and end-of-life medicines—insights from pharmaceutical care process into waste medicines management. Environ Sci Pollut Res. 2021;28(41):58170–88.
17. de Oliveira Neto JF, Silva MM, Machado Santos S. A mini-review of E-waste management in Brazil: Perspectives and challenges. CLEAN–Soil Air Water. 2019;47(9):1900152.
18. Desai M, Njoku A, Nimo-Sefah L. Comparing environmental policies to reduce pharmaceutical pollution and address disparities. Int J Environ Res Public Health. 2022;19(14):8292.
19. Eckstein GE. Drugs on Tap: Managing Pharmaceuticals in Our Nation's Waters. NYU Envtl LJ. 2015;23:37.
20. Ehrhart AL, Granek EF, Nielsen-Pincus M, Horn DA. Leftover drug disposal: Customer behavior, pharmacist recommendations, and obstacles to drug take-back box implementation. Waste Manag. 2020;118:416–25.
21. Fenta BA. Waste management in the case of Bahir Dar City near Lake Tana shore in Northwestern Ethiopia: A review. Afr J Environ Sci Technol. 2017;11(8):393–412.
22. Fidora AF. Knowledge and barriers to safe disposal of pharmaceutical products entering the environment. Walden University; 2017.
23. Freitas LAA, Radis-Baptista G. Pharmaceutical pollution and disposal of expired, unused, and unwanted medicines in the Brazilian context. J Xenobiotics. 2021;11(2):61–76.
24. Gill YQ, Khurshid M, Abid U, Ijaz MW. Review of hospital plastic waste management strategies for Pakistan. Environ Sci Pollut Res. 2021;1–14.
25. Gutberlet J. Recovering resources-recycling citizenship: Urban poverty reduction in Latin America. Routledge; 2016.
26. Hu XY, Logue M, Robinson N. Antimicrobial resistance is a global problem–a UK perspective. Eur J Integr Med. 2020;36:101136.
27. Imad EMN, Asim AE, Tasneem JMS, Wadha MM, Bhagavathula AS. Management of post-consumer pharmaceutical waste: an overview. SOJ Pharm Pharm Sci. 2017;4(5):1–5.
28. Jasovský D, Littmann J, Zorzet A, Cars O. Antimicrobial resistance—a threat to the world’s sustainable development. Ups J Med Sci. 2016;121(3):159–64.
29. Jassim SA, Limoges RG. Natural solution to antibiotic resistance: bacteriophages ‘The Living Drugs’. World J Microbiol Biotechnol. 2014;30(8):2153–70.
30. Jjemba PK. Pharma-ecology: the occurrence and fate of pharmaceuticals and personal care products in the environment. John Wiley & Sons; 2018.
31. Jjemba PK. Pharma-ecology: the occurrence and fate of pharmaceuticals and personal care products in the environment. John Wiley & Sons; 2018.
32. Kettle AJ, Albrett AM, Chapman AL, Dickerhof N, Forbes LV, Khalilova I, *et al*. Measuring chlorine bleach in biology and medicine. Biochim Biophys Acta Gen Subj. 2014;1840(2):781–93.

33. Khan NA, Vambol V, Vambol S, Bolibrukh B, Sillanpaa M, Changani F, *et al*. Hospital effluent guidelines and legislation scenario around the globe: A critical review. J Environ Chem Eng. 2021;9(5):105874.
34. Khor M. The Global Threat of Antimicrobial Resistance and the Challenges and Needs of Developing Countries. Third World Network; 2019.
35. King S, Hutchinson SA, Boxall NJ. Advanced recycling technologies to address Australia's plastic waste. Commonwealth Scientific and Industrial Research Organisation; 2021.
36. Kong Q, He X, Feng Y, Miao MS, Wang Q, Du YD, *et al*. Pollutant removal and microorganism evolution of activated sludge under ofloxacin selection pressure. Bioresour Technol. 2017;241:849–56.
37. Kotwani A, Joshi J, Kaloni D. Pharmaceutical effluent: a critical link in the interconnected ecosystem promoting antimicrobial resistance. Environ Sci Pollut Res. 2021;28(25):32111–24.
38. Krzemiński P, Popowska M. Treatment technologies for removal of antibiotics, antibiotic resistance bacteria and antibiotic-resistant genes. Antibiotics and Antimicrobial Resistance Genes: Environmental Occurrence and Treatment Technologies. 2020;415–34.
39. Kumar A, Pal D. Antibiotic resistance and wastewater: Correlation, impact and critical human health challenges. J Environ Chem Eng. 2018;6(1):52–8.
40. Kurniawan TA, Maiurova A, Kustikova M, Bykovskaia E, Othman MHD, Goh HH. Accelerating sustainability transition in St. Petersburg (Russia) through digitalization-based circular economy in waste recycling industry: A strategy to promote carbon neutrality in era of Industry 4.0. J Clean Prod. 2022;363:132452.
41. Lago NC, Kolling C, Auler MS. Consumer Medicines Disposal Behavior: Insights Towards a More Sustainable. Ind Eng Oper Manag. 2022;400:181.
42. Landecker H. Antibiotic resistance and the biology of history. Body Soc. 2016;22(4):19–52.
43. Landecker H. Antimicrobials before antibiotics: war, peace, and disinfectants. Palgrave Commun. 2019;5(1).
44. Le Quesne WJ, Baker-Austin C, Verner-Jeffreys DW, Al-Sarawi HA, Balkhy HH, Lyons BP. Antimicrobial resistance in the Gulf Cooperation Council region: A proposed framework to assess threats, impacts and mitigation measures associated with AMR in the marine and aquatic environment. Environ Int. 2018;121:1003–10.
45. Le Roux J, Gallard H, Croué JP. Chloramination of nitrogenous contaminants (pharmaceuticals and pesticides): NDMA and halogenated DBPs formation. Water Res. 2011;45(10):3164–74.
46. Lees P, Pelligand L, Giraud E, Toutain PL. A history of antimicrobial drugs in animals: Evolution and revolution. J Vet Pharmacol Ther. 2021;44(2):137–71.
47. Li D, Qi R, Yang M, Zhang Y, Yu T. Bacterial community characteristics under long-term antibiotic selection pressures. Water Res. 2011;45(18):6063–73.
48. Li S, Zhang C, Li F, Hua T, Zhou Q, Ho SH. Technologies towards antibiotic resistance genes (ARGs) removal from aquatic environment: a critical review. J Hazard Mater. 2021;411:125148.
49. Li WC. Occurrence, sources, and fate of pharmaceuticals in aquatic environment and soil. Environ Pollut. 2014;187:193–201.
50. Lima T, Domingues S, Da Silva GJ. Manure as a potential hotspot for antibiotic resistance dissemination by horizontal gene transfer events. Vet Sci. 2020;7(3):110.
51. Lofrano G, Pedrazzani R, Libralato G, Carotenuto M. Advanced oxidation processes for antibiotics removal: a review. Curr Org Chem. 2017;21(12):1054–67.
52. Luo Y, Reimers K, Yang L, Lin J. Household drug management practices of residents in a second-tier city in China: Opportunities for reducing drug waste and environmental pollution. Int J Environ Res Public Health. 2021;18(16):8544.
53. Luongo G, Previtera L, Ladhari A, Di Fabio G, Zarrelli A. Peracetic acid vs. sodium hypochlorite: Degradation and transformation of drugs in wastewater. Molecules. 2020;25(10):2294.
54. Mahmood MA. An evaluation of British Columbia's medications return program as a management framework for collecting unused/expired pharmaceuticals [PhD thesis]. Toronto Metropolitan University; 2010.
55. Makki M, Hassali MA, Awaisu A, Hashmi F. The prevalence of unused medications in homes. Pharmacy. 2019;7(2):61.
56. Mallick PK, Salling KB, Pigosso DC, McAloone TC. Designing take-back for single use medical devices: the case of ReturpenTM. J Diabetes Sci Technol. 2022;16(6):1363–9.
57. Manyi-Loh C, Mamphweli S, Meyer E, Okoh A. Antibiotic use in agriculture and its consequential resistance in environmental sources: potential public health implications. Molecules. 2018;23(4):795.
58. Marican A, Durán-Lara EF. A review on pesticide removal through different processes. Environ Sci Pollut Res. 2018;25:2051–64.
59. Mazivila SJ, Ricardo IA, Leitão JM, da Silva JCE. A review on advanced oxidation processes: From classical to new perspectives coupled to two-and multi-way calibration strategies to monitor degradation of contaminants in environmental samples. Trends Environ Anal Chem. 2019;24:e00072.
60. McCarthy B, Apori SO, Giltrap M, Bhat A, Curtin J, Tian F. Hospital effluents and wastewater treatment plants: a source of oxytetracycline and antimicrobial-resistant bacteria in seafood. Sustainability. 2021;13(24):13967.
61. Merker M, Tueffers L, Vallier M, Groth EE, Sonnenkalb L, Unterweger D, *et al*. Evolutionary approaches to combat antibiotic resistance: opportunities and challenges for precision medicine. Front Immunol. 2020;11:1938.
62. Mitkidis K, Obolevich V, Chrysochou P, Mitkidis P. Harmonisation of pharmaceutical take-back systems in the EU. Eur J Health Law. 2021;28(5):445–71.
63. Mohapatra DP, Brar SK, Tyagi RD, Picard P, Surampalli RY. Analysis and advanced oxidation treatment of a persistent pharmaceutical compound in wastewater and wastewater sludge-carbamazepine. Sci Total Environ. 2014;470:58–75.
64. Monapathi ME, Oguegbulu JC, Adogo L, Klink M, Okoli B, Mtunzi F, *et al*. Pharmaceutical pollution: Azole antifungal drugs and resistance of opportunistic pathogenic yeasts in wastewater and environmental water. Appl Environ Soil Sci. 2021;2021(1):9985398.
65. Musee N. Nanowastes and the environment: Potential

new waste management paradigm. Environ Int. 2011;37(1):112–28.
66. Muth MK, Birney C, Cuéllar A, Finn SM, Freeman M, Galloway JN, *et al*. A systems approach to assessing environmental and economic effects of food loss and waste interventions in the United States. Sci Total Environ. 2019;685:1240–54.
67. Muthuraman L, Ramaswamy S. Solid Waste Management. MJP Publisher; 2019.
68. Nagarnaik PM, Batt AL, Boulanger B. Healthcare facility effluents as point sources of select pharmaceuticals to municipal wastewater. Water Environ Res. 2012;84(4):339–45.
69. Nciri N, Kim N, Caron A. Unlocking the Hidden Potential of Cosmetics Waste for Building Sustainable Green Pavements in the Future: A Case Study of Discarded Lipsticks. Molecules. 2022;27(5):1697.
70. Nguyen AQ, Vu HP, Nguyen LN, Wang Q, Djordjevic SP, Donner E, *et al*. Monitoring antibiotic resistance genes in wastewater treatment: Current strategies and future challenges. Sci Total Environ. 2021;783:146964.
71. Nyaga MN, Nyagah DM, Njagi A. Pharmaceutical waste: Overview, management, and impact of improper disposal. 2020.
72. Ojemaye CY, Petrik L. Pharmaceuticals in the marine environment: a review. Environ Rev. 2019;27(2):151–65.
73. Oliveira TS, Al Aukidy M, Verlicchi P. Occurrence of common pollutants and pharmaceuticals in hospital effluents. Hospital wastewaters: characteristics, management, treatment and environmental risks. 2018;17–32.
74. Oliveira TS, Murphy M, Mendola N, Wong V, Carlson D, Waring L. Characterization of pharmaceuticals and personal care products in hospital effluent and waste water influent/effluent by direct-injection LC-MS-MS. Sci Total Environ. 2015;518:459–78.
75. Oluwole AO, Omotola EO, Olatunji OS. Pharmaceuticals and personal care products in water and wastewater: a review of treatment processes and use of photocatalyst immobilized on functionalized carbon in AOP degradation. BMC Chem. 2020;14:1–29.
76. Ongondo FO, Williams ID, Cherrett TJ. How are WEEE doing? A global review of the management of electrical and electronic wastes. Waste Manag. 2011;31(4):714–30.
77. Oppong PK, Phiri MA. The Influence of Packaging and Brand Equity on Over-the-Counter Herbal Medicines in Kumasi, Ghana [PhD thesis]. University of KwaZulu-Natal; 2018.
78. Ort C, Lawrence MG, Reungoat J, Eaglesham G, Carter S, Keller J. Determining the fraction of pharmaceutical residues in wastewater originating from a hospital. Water Res. 2010;44(2):605–15.
79. Patel S, Dora M, Hahladakis JN, Iacovidou E. Opportunities, challenges and trade-offs with decreasing avoidable food waste in the UK. Waste Manag Res. 2021;39(3):473–88.
80. Paut Kusturica M, Tomas A, Sabo A. Disposal of unused drugs: knowledge and behavior among people around the world. Rev Environ Contam Toxicol. 2017;240:71–104.
81. Pereira ALA, de Vasconcelos Barros RT, Pereira SR. Pharmacopollution and Household Waste Medicine (HWM): how reverse logistics is environmentally important to Brazil. Environ Sci Pollut Res. 2017;24(31):24061–75.
82. Pikkemaat MG, Yassin H, Fels-Klerx HJ, Berendsen BJA. Antibiotic residues and resistance in the environment. RIKILT; 2016.
83. Postigo C, Richardson SD. Transformation of pharmaceuticals during oxidation/disinfection processes in drinking water treatment. J Hazard Mater. 2014;279:461–75.
84. Pruden A, Larsson DJ, Amézquita A, Collignon P, Brandt KK, Graham DW, *et al*. Management options for reducing the release of antibiotics and antibiotic resistance genes to the environment. Environ Health Perspect. 2013;121(8):878–85.
85. Quintana JB, Rodil R, López-Mahía P, Muniategui-Lorenzo S, Prada-Rodríguez D. Investigating the chlorination of acidic pharmaceuticals and by-product formation aided by an experimental design methodology. Water Res. 2010;44(1):243–55.
86. Reggiane de Carvalho Costa L, Guerra Pacheco Nunes K, Amaral Féris L. Ultrasound as an advanced oxidative process: A review on treating pharmaceutical compounds. Chem Eng Technol. 2021;44(10):1744–58.
87. Reid L. Antimicrobial resistance and social inequalities in health: Considerations of justice. Ethics and drug resistance: Collective responsibility for global public health. 2020;257–78.
88. Rogowska J, Zimmermann A. Household pharmaceutical waste disposal as a global problem—a review. Int J Environ Res Public Health. 2022;19(23):15798.
89. Sahota NK, Sharma R. Insight into pharmaceutical waste management by employing bioremediation techniques to restore environment. Handbook of Solid Waste Management: Sustainability through Circular Economy. 2021;1–32.
90. Santos LH, Gros M, Rodriguez-Mozaz S, Delerue-Matos C, Pena A, Barceló D, *et al*. Contribution of hospital effluents to the load of pharmaceuticals in urban wastewaters: identification of ecologically relevant pharmaceuticals. Sci Total Environ. 2013;461:302–16.
91. Sartelli M, Hardcastle TC, Catena F, Chichom-Mefire A, Coccolini F, Dhingra S, *et al*. Antibiotic use in low and middle-income countries and the challenges of antimicrobial resistance in surgery. Antibiotics. 2020;9(8):497.
92. Serwecińska L. Antimicrobials and antibiotic-resistant bacteria: a risk to the environment and to public health. Water. 2020;12(12):3313.
93. Shi T, Petruzzi NC, Chhajed D. The effects of patent extension and take-back regulation on green pharmacy. Manuf Serv Oper Manag. 2022;24(2):810–26.
94. Šimatović A, Udiković-Kolić N. Antibiotic resistance in pharmaceutical industry effluents and effluent-impacted environments. Antibiotic resistance in the environment: A worldwide overview. 2019;101–22.
95. Singer AC, Shaw H, Rhodes V, Hart A. Review of antimicrobial resistance in the environment and its relevance to environmental regulators. Front Microbiol. 2016;7:1728.
96. Singh JS, Kumar A, Rai AN, Singh DP. Cyanobacteria: a precious bio-resource in agriculture, ecosystem, and

environmental sustainability. Front Microbiol. 2016;7:529.
97. Singh N, Yeh PJ. Suppressive drug combinations and their potential to combat antibiotic resistance. J Antibiot. 2017;70(11):1033–42.
98. Slaughter RJ, Watts M, Vale JA, Grieve JR, Schep LJ. The clinical toxicology of sodium hypochlorite. Clin Toxicol. 2019;57(5):303–11.
99. Stoddard KI, Huggett DB. Pharmaceutical take back programs. Human Pharmaceuticals in the Environment: Current and Future Perspectives. 2012;257–85.
100. Thane G. A Call to Action: An Evidence Review on Pharmaceutical Disposal in the Context of Antimicrobial Resistance in Canada. 2021.
101. Thongsamer T, Neamchan R, Blackburn A, Acharya K, Sutheeworapong S, Tirachulee B, *et al*. Environmental antimicrobial resistance is associated with faecal pollution in Central Thailand's coastal aquaculture region. J Hazard Mater. 2021;416:125718.
102. Truong LB, Medina-Cruz D, Mostafavi E, Rabiee N. Selenium nanomaterials to combat antimicrobial resistance. Molecules. 2021;26(12):3611.
103. Vatovec C, Kolodinsky J, Callas P, Hart C, Gallagher K. Pharmaceutical pollution sources and solutions: Survey of human and veterinary medication purchasing, use, and disposal. J Environ Manage. 2021;285:112106.
104. Vatovec C, Van Wagoner E, Evans C. Investigating sources of pharmaceutical pollution: Survey of over-the-counter and prescription medication purchasing, use, and disposal practices among university students. J Environ Manage. 2017;198:348–52.
105. Verlicchi P, Al Aukidy M, Galletti A, Petrovic M, Barceló D. Hospital effluent: investigation of the concentrations and distribution of pharmaceuticals and environmental risk assessment. Sci Total Environ. 2012;430:109–18.
106. Wang J, Zhuan R. Degradation of antibiotics by advanced oxidation processes: An overview. Sci Total Environ. 2020;701:135023.
107. Wang X, Zhou B, Yang H, Wang X, Xie Y. Effect of oxidation on nitro-based pharmaceutical degradation and trichloronitromethane formation. Chemosphere. 2016;146:154–61.
108. Worrell E, Reuter MA, editors. Handbook of Recycling: State-of-the-art for Practitioners, Analysts, and Scientists. Newnes; 2014.
109. Xie Y, Breen L. Who cares wins? A comparative analysis of household waste medicines and batteries reverse logistics systems: The case of the NHS (UK). Supply Chain Manag. 2014;19(4):455–74.